Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies

S. M. Gapstur; A. V. Patel; E. Banks; L. Dal Maso; R. Talamini; A. Chetrit; G. Hirsh-Yechezkel; F. Lubin; S. Sadetzki; V. Beral; D. Bull; B. Cairns; B. Crossley; K. Gaitskell; A. Goodill; J. Green; C. Hermon; T. Key; K. Moser; G. Reeves; F. Sitas; R. Collins; R. Peto; C. A. Gonzalez; N. Lee; P. Marchbanks; H. W. Ory; H. B. Peterson; P. A. Wingo; N. Martin; S. Silpisornkosol; C. Theetranont; B. Boosiri; S. Chutivongse; P. Jimakorn; P. Virutamasen; C. Wongsrichanalai; M. T. Goodman; O. Lidegaard; S. K. Kjaer; L. S. Morch; S. K. Kjaer; A. Tjonneland; T. Byers; T. Rohan; B. Mosgaard; M. Vessey; D. Yeates; N. C. Onland-Moret; P. H. M. Peeters

doi:10.1016/S0140-6736(14)61687-1

Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies

S. M. Gapstur^*, A. V. Patel, E. Banks, L. Dal Maso, R. Talamini, A. Chetrit, G. Hirsh-Yechezkel, F. Lubin, S. Sadetzki, V. Beral, D. Bull, B. Cairns, B. Crossley, K. Gaitskell, A. Goodill, J. Green, C. Hermon, T. Key, K. Moser, G. ReevesF. Sitas, R. Collins, R. Peto, C. A. Gonzalez, N. Lee, P. Marchbanks, H. W. Ory, H. B. Peterson, P. A. Wingo, N. Martin, S. Silpisornkosol, C. Theetranont, B. Boosiri, S. Chutivongse, P. Jimakorn, P. Virutamasen, C. Wongsrichanalai, M. T. Goodman, O. Lidegaard, S. K. Kjaer, L. S. Morch, S. K. Kjaer, A. Tjonneland, T. Byers, T. Rohan, B. Mosgaard, M. Vessey, D. Yeates, N. C. Onland-Moret, P. H. M. Peeters,

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Background Half the epidemiological studies with information about menopausal hormone therapy and ovarian cancer risk remain unpublished, and some retrospective studies could have been biased by selective participation or recall. We aimed to assess with minimal bias the effects of hormone therapy on ovarian cancer risk.

Methods Individual participant datasets from 52 epidemiological studies were analysed centrally. The principal analyses involved the prospective studies (with last hormone therapy use extrapolated forwards for up to 4 years). Sensitivity analyses included the retrospective studies. Adjusted Poisson regressions yielded relative risks (RRs) versus never-use.

Findings During prospective follow-up, 12 110 postmenopausal women, 55% (6601) of whom had used hormone therapy, developed ovarian cancer. Among women last recorded as current users, risk was increased even with

Interpretation The increased risk may well be largely or wholly causal; if it is, women who use hormone therapy for 5 years from around age 50 years have about one extra ovarian cancer per 1000 users and, if its prognosis is typical, about one extra ovarian cancer death per 1700 users.

Original language	English
Pages (from-to)	1835-1842
Number of pages	8
Journal	The Lancet
Volume	385
Issue number	9980
DOIs	https://doi.org/10.1016/S0140-6736(14)61687-1
Publication status	Published - 9 May 2015

Keywords

WOMEN
THERAPY
HEALTH

Access to Document

10.1016/S0140-6736(14)61687-1

Cite this

Gapstur, S. M., Patel, A. V., Banks, E., Dal Maso, L., Talamini, R., Chetrit, A., Hirsh-Yechezkel, G., Lubin, F., Sadetzki, S., Beral, V., Bull, D., Cairns, B., Crossley, B., Gaitskell, K., Goodill, A., Green, J., Hermon, C., Key, T., Moser, K. (2015). Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. The Lancet, 385(9980), 1835-1842. https://doi.org/10.1016/S0140-6736(14)61687-1

@article{d3e8dec13f794305989cc74d0d20182a,

title = "Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies",

abstract = "Background Half the epidemiological studies with information about menopausal hormone therapy and ovarian cancer risk remain unpublished, and some retrospective studies could have been biased by selective participation or recall. We aimed to assess with minimal bias the effects of hormone therapy on ovarian cancer risk.Methods Individual participant datasets from 52 epidemiological studies were analysed centrally. The principal analyses involved the prospective studies (with last hormone therapy use extrapolated forwards for up to 4 years). Sensitivity analyses included the retrospective studies. Adjusted Poisson regressions yielded relative risks (RRs) versus never-use.Findings During prospective follow-up, 12 110 postmenopausal women, 55% (6601) of whom had used hormone therapy, developed ovarian cancer. Among women last recorded as current users, risk was increased even withInterpretation The increased risk may well be largely or wholly causal; if it is, women who use hormone therapy for 5 years from around age 50 years have about one extra ovarian cancer per 1000 users and, if its prognosis is typical, about one extra ovarian cancer death per 1700 users.",

keywords = "WOMEN, THERAPY, HEALTH",

author = "Gapstur, {S. M.} and Patel, {A. V.} and E. Banks and {Dal Maso}, L. and R. Talamini and A. Chetrit and G. Hirsh-Yechezkel and F. Lubin and S. Sadetzki and V. Beral and D. Bull and B. Cairns and B. Crossley and K. Gaitskell and A. Goodill and J. Green and C. Hermon and T. Key and K. Moser and G. Reeves and F. Sitas and R. Collins and R. Peto and Gonzalez, {C. A.} and N. Lee and P. Marchbanks and Ory, {H. W.} and Peterson, {H. B.} and Wingo, {P. A.} and N. Martin and S. Silpisornkosol and C. Theetranont and B. Boosiri and S. Chutivongse and P. Jimakorn and P. Virutamasen and C. Wongsrichanalai and Goodman, {M. T.} and O. Lidegaard and Kjaer, {S. K.} and Morch, {L. S.} and Kjaer, {S. K.} and A. Tjonneland and T. Byers and T. Rohan and B. Mosgaard and M. Vessey and D. Yeates and Onland-Moret, {N. C.} and Peeters, {P. H. M.}",

year = "2015",

month = may,

day = "9",

doi = "10.1016/S0140-6736(14)61687-1",

language = "English",

volume = "385",

pages = "1835--1842",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier",

number = "9980",

}

Gapstur, SM, Patel, AV, Banks, E, Dal Maso, L, Talamini, R, Chetrit, A, Hirsh-Yechezkel, G, Lubin, F, Sadetzki, S, Beral, V, Bull, D, Cairns, B, Crossley, B, Gaitskell, K, Goodill, A, Green, J, Hermon, C, Key, T, Moser, K, Reeves, G, Sitas, F, Collins, R, Peto, R, Gonzalez, CA, Lee, N, Marchbanks, P, Ory, HW, Peterson, HB, Wingo, PA, Martin, N, Silpisornkosol, S, Theetranont, C, Boosiri, B, Chutivongse, S, Jimakorn, P, Virutamasen, P, Wongsrichanalai, C, Goodman, MT, Lidegaard, O, Kjaer, SK, Morch, LS, Kjaer, SK, Tjonneland, A, Byers, T, Rohan, T, Mosgaard, B, Vessey, M, Yeates, D, Onland-Moret, NC, Peeters, PHM 2015, 'Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies', The Lancet, vol. 385, no. 9980, pp. 1835-1842. https://doi.org/10.1016/S0140-6736(14)61687-1

TY - JOUR

T1 - Menopausal hormone use and ovarian cancer risk

T2 - individual participant meta-analysis of 52 epidemiological studies

AU - Gapstur, S. M.

AU - Patel, A. V.

AU - Banks, E.

AU - Dal Maso, L.

AU - Talamini, R.

AU - Chetrit, A.

AU - Hirsh-Yechezkel, G.

AU - Lubin, F.

AU - Sadetzki, S.

AU - Beral, V.

AU - Bull, D.

AU - Cairns, B.

AU - Crossley, B.

AU - Gaitskell, K.

AU - Goodill, A.

AU - Green, J.

AU - Hermon, C.

AU - Key, T.

AU - Moser, K.

AU - Reeves, G.

AU - Sitas, F.

AU - Collins, R.

AU - Peto, R.

AU - Gonzalez, C. A.

AU - Lee, N.

AU - Marchbanks, P.

AU - Ory, H. W.

AU - Peterson, H. B.

AU - Wingo, P. A.

AU - Martin, N.

AU - Silpisornkosol, S.

AU - Theetranont, C.

AU - Boosiri, B.

AU - Chutivongse, S.

AU - Jimakorn, P.

AU - Virutamasen, P.

AU - Wongsrichanalai, C.

AU - Goodman, M. T.

AU - Lidegaard, O.

AU - Kjaer, S. K.

AU - Morch, L. S.

AU - Kjaer, S. K.

AU - Tjonneland, A.

AU - Byers, T.

AU - Rohan, T.

AU - Mosgaard, B.

AU - Vessey, M.

AU - Yeates, D.

AU - Onland-Moret, N. C.

AU - Peeters, P. H. M.

PY - 2015/5/9

Y1 - 2015/5/9

N2 - Background Half the epidemiological studies with information about menopausal hormone therapy and ovarian cancer risk remain unpublished, and some retrospective studies could have been biased by selective participation or recall. We aimed to assess with minimal bias the effects of hormone therapy on ovarian cancer risk.Methods Individual participant datasets from 52 epidemiological studies were analysed centrally. The principal analyses involved the prospective studies (with last hormone therapy use extrapolated forwards for up to 4 years). Sensitivity analyses included the retrospective studies. Adjusted Poisson regressions yielded relative risks (RRs) versus never-use.Findings During prospective follow-up, 12 110 postmenopausal women, 55% (6601) of whom had used hormone therapy, developed ovarian cancer. Among women last recorded as current users, risk was increased even withInterpretation The increased risk may well be largely or wholly causal; if it is, women who use hormone therapy for 5 years from around age 50 years have about one extra ovarian cancer per 1000 users and, if its prognosis is typical, about one extra ovarian cancer death per 1700 users.

AB - Background Half the epidemiological studies with information about menopausal hormone therapy and ovarian cancer risk remain unpublished, and some retrospective studies could have been biased by selective participation or recall. We aimed to assess with minimal bias the effects of hormone therapy on ovarian cancer risk.Methods Individual participant datasets from 52 epidemiological studies were analysed centrally. The principal analyses involved the prospective studies (with last hormone therapy use extrapolated forwards for up to 4 years). Sensitivity analyses included the retrospective studies. Adjusted Poisson regressions yielded relative risks (RRs) versus never-use.Findings During prospective follow-up, 12 110 postmenopausal women, 55% (6601) of whom had used hormone therapy, developed ovarian cancer. Among women last recorded as current users, risk was increased even withInterpretation The increased risk may well be largely or wholly causal; if it is, women who use hormone therapy for 5 years from around age 50 years have about one extra ovarian cancer per 1000 users and, if its prognosis is typical, about one extra ovarian cancer death per 1700 users.

KW - WOMEN

KW - THERAPY

KW - HEALTH

U2 - 10.1016/S0140-6736(14)61687-1

DO - 10.1016/S0140-6736(14)61687-1

M3 - Article

SN - 0140-6736

VL - 385

SP - 1835

EP - 1842

JO - The Lancet

JF - The Lancet

IS - 9980

ER -

Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies

Abstract

Keywords

Access to Document

Fingerprint

Cite this